Andina Capital Management LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Andina Capital Management LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 516 shares of the pharmaceutical company’s stock after selling 28 shares during the period. Andina Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $208,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VRTX. Linden Thomas Advisory Services LLC boosted its position in Vertex Pharmaceuticals by 9.5% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 7,441 shares of the pharmaceutical company’s stock valued at $2,996,000 after acquiring an additional 644 shares in the last quarter. Pflug Koory LLC lifted its stake in shares of Vertex Pharmaceuticals by 4.1% during the 4th quarter. Pflug Koory LLC now owns 2,018 shares of the pharmaceutical company’s stock worth $813,000 after purchasing an additional 79 shares during the last quarter. Goelzer Investment Management Inc. boosted its position in Vertex Pharmaceuticals by 1.5% during the fourth quarter. Goelzer Investment Management Inc. now owns 1,915 shares of the pharmaceutical company’s stock valued at $771,000 after purchasing an additional 29 shares in the last quarter. Brighton Jones LLC grew its stake in Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the last quarter. Finally, Montecito Bank & Trust raised its holdings in Vertex Pharmaceuticals by 2.5% in the fourth quarter. Montecito Bank & Trust now owns 1,659 shares of the pharmaceutical company’s stock worth $668,000 after purchasing an additional 40 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Down 0.0 %

VRTX stock opened at $439.62 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The company’s 50-day simple moving average is $435.36 and its 200-day simple moving average is $464.66.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $3.67 earnings per share. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Barclays cut their price objective on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Canaccord Genuity Group increased their price objective on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday. Finally, Royal Bank of Canada increased their price target on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $494.84.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.